Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Firstline pembrolizumab for metastatic urothelial cancer

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.10.16
Views: 2141

Dr Arjun Balar - NYU Langone Medical Center, New York, USA

Dr Balar speaks with ecancertv at ESMO 2016 about the outcomes of patients receiving immune checkpoint therapy as a first line treatment against metastatic urothelial cancer.

You can read the news coverage of this story here.

These results advance on those of the IMvigor210 trial, described by Dr Balar at ASCO 2016.

Checkpoint therapy for metastatic urothelial cancer was also discussed by Dr Matthew Galsky.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation